Practo · Medical Value Travel
Practo · Medical Value Travel

India's inbound medical tourism,
converted at the source.

Practo already owns the demand — roughly 110,000 international visits a month on doctor pages. This is the plan to convert that demand into hospital admissions, and the P&L that follows — built all the way to EBIT, in ₹ lakh.

₹49.4L Year-1 EBIT
₹2.59Cr Year-3 EBIT
644,387 medical arrivals (2024)
110K/mo non-India traffic
profitable from Month 7
The Market

A $7.7B inbound market, growing — but dangerously concentrated.

India is one of the world's top medical-value-travel destinations. Demand is large and growing, but today it leans heavily on a single source country — which is both the risk and the opportunity to diversify.

$7.69B
India inbound MVT (2024)
$14.31B
Projected by 2029
644,387
Medical arrivals 2024 (vs 182,945 in 2020)
~75%
From Bangladesh alone
131,856
Arrivals Jan–Apr 2025
−67%

Concentration is the risk — and the opening

Bangladesh was ~75% of 2024 arrivals; medical arrivals fell 44% / 67% YoY in Nov / Dec 2024 on geopolitical strain. Diversifying toward GCC, Africa and Iraq is higher-value and more durable — exactly the geo-mix Practo's traffic can steer.

Source:
Bureau of
Immigration
Market sizes vary by methodology and are directional. Arrivals: Bureau of Immigration, reported in press. Full sourcing on the workbook's Sources tab.
Competitive Landscape

Facilitators are small. Hospitals are big. Nobody owns demand like Practo.

India inbound

Vaidam

₹16.4 Cr revenue (FY24) · ~207K visits/mo · NABH-first marketplace, broad specialties.

AI discovery

CureMeAbroad

~$3.5M ARR* · $600K pre-seed · AI cost estimator, 6,000 hospitals — closest to our thesis.

US outbound

Medical Tourism Corp

~$25M* · since 2007 · US/Canada → Mexico, India, Thailand; bariatric / dental / cosmetic.

Global

Bookimed

~970K enquiries · #1 by verified reviews · Turkey / Korea / Thailand-led, broad.

Hospital arms are the giants

Fortis MVT revenue ₹639 Cr (FY26); Apollo intl-patient revenue +28% YoY — but captive to their own hospitals.

Practo's edge

~110K/mo non-India doctor-page traffic — targeted demand that rivals or exceeds most facilitators' entire site.

The shared gap

Most buy traffic and lack continuity-of-care. Practo generates demand and has 40L+ verified reviews + Health Feed.

The wedge

A demand-gen engine plus the Assured verified network — neither of which rivals can easily copy.

*Medical Tourism Corp ~$25M and CureMeAbroad ~$3.5M ARR are third-party / self-reported estimates (unverified). Vaidam revenue: Tracxn. Traffic: SimilarWeb.
Capability Scorecard

Four capabilities. Two are strong. Two are the whole game.

1
Acquire web trafficOrganic doctor-page traffic from outside India already exists (~110K/mo) — the asset, not yet steered for medical-value-travel intent.
5 / 10
2
Convert web traffic → leadsMissing the basics: language, locale, OTP, telephony, WhatsApp and the right value-proposition messaging.
1 / 10
3
Convert leads → attributable walk-ins & IPsNo visa / travel / translator path — valid leads leak to whoever provides last-mile services.
1 / 10
4
Right take-rate contract with hospitalsCommercial terms largely in place — the basis for the 20% take in the model.
2

The binding constraints

Capabilities #2 and #3 (both 1/10) gate the two conversion ramps in the model. Fixing them is what moves admissions — and EBIT. #1 and #4 are strengths to leverage.

Self-
assessed
/ 10
Mitigation Plan

Close the gaps — build two, partner one, leverage one.

1

Acquire traffic

Keyword research per target geo, then build new localised landing pages per geo / procedure to capture and steer demand.

2

Traffic → leads

Build the funnel tech: OTP, telephony, locale & language, WhatsApp, and sharpened value-prop messaging.

3

Leads → walk-ins

Partner with a last-mile provider (visa, travel, translator) for a fee — with attribution designed in so leads don't leak.

4

Take-rate contracts

Leverage the Assured network, and use medical tourism as the wedge into yet-to-hunt Super KAs (top-tier hospital key accounts).

Critical path

#2 (tech) and #3 (partner) unblock conversion; #1 and #4 compound the upside but don't move it alone.

Build vs partner

Partnering #3 is fast and low-capex — the trade-off is an ongoing fee + dependency.

Attribution is the catch

If the partner owns the patient, you recreate the leakage. Own the relationship and the record.

Next model input

Fold the last-mile fee into the P&L so EBIT reflects the true cost of capability #3.

The Model · ₹ lakh

Built to EBIT — and profitable from Month 7.

A fully tunable P&L: traffic → leads → admissions → revenue → EBIT, with conversion ramping as the build lands. Inputs are deliberately conservative (1% page conversion; 1.5–2.5% lead-to-admission).

Traffic
110K / mo
Page conv.
→ 1%
Lead → IP
1.5–2.5%
Admissions Y1
~212
EBIT Y1
₹49.4 L
₹339L
Year-1 revenue
₹49.4L
Year-1 EBIT · 14.6% margin
₹2.59Cr
Year-3 EBIT · 28.6% margin
Month 7
Cumulative breakeven
−₹13L
Peak cash need (Month 3)
Figures denominated live in the workbook (₹ lakh / crore). Pre last-mile-partner fee (mitigation #3) — a cost still to be folded into the P&L.
The Thesis

Own the demand. Build the conversion.

Practo is the only player that generates international demand instead of buying it — and already runs the Assured verified network. The opportunity is to close two conversion gaps and turn existing traffic into a profitable medical-tourism line.

110K/mo demand we already own
Fix #2 — funnel tech
Partner #3 — last-mile
Leverage Assured + Super KAs
₹49.4L EBIT Y1 → ₹2.59Cr Y3
Profitable from Month 7
navigate · F fullscreen